marked.bio

Company

Verastem

5 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

VS-7375 4cetuximab 3panitumumab 2defactinib 2pembrolizumab 1avutometinib 1sotorasib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

5 of 8 trials shown

  1. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07659782

    VS-7375

    Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

    KRAS G12DNon-Small Cell Lung Cancer

  2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07659795

    VS-7375cetuximabpanitumumabmFOLFOX6

    Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

    KRAS G12DColorectal Cancer

  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07644559

    VS-7375cetuximabpanitumumab

    Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

    KRAS G12DPancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS

  4. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    Recruiting Phase 1/2 Verastem Started 2025Primary completion 2028-12 NCT07020221

    VS-7375cetuximabcarboplatinpemetrexedpembrolizumabgemcitabinenab-paclitaxeldefactinibmidazolamRepaglinide

    …cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation.

    KRAS G12DPancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult

  5. Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

    Active, not recruiting Phase 1/2 Verastem Started 2022Primary completion 2026-06 NCT05074810

    avutometinib FDAsotorasib FDA EUdefactinib FDA

    Known KRAS G12C mutation

    KRAS G12CNon Small Cell Lung Cancer, KRAS Activating Mutation